Post by selluwud on Aug 13, 2015 12:56:39 GMT
finance.yahoo.com/news/immunocellular-therapeutics-reaches-agreement-fda-100000647.html
IMUC missed it's endpoints in a Phase 2 trial, but data revealed some promise for selected groups of patients. I held a considerable amount of shares and sold during the precipitous drop when P2 results came out. I have held onto some shares just in case they could recover. Over a million shares traded in pre-market so far. Still a long way to go.
IMUC missed it's endpoints in a Phase 2 trial, but data revealed some promise for selected groups of patients. I held a considerable amount of shares and sold during the precipitous drop when P2 results came out. I have held onto some shares just in case they could recover. Over a million shares traded in pre-market so far. Still a long way to go.